169 related articles for article (PubMed ID: 22716277)
1. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.
Wu JM; Staton CA
Expert Opin Drug Discov; 2012 Aug; 7(8):723-43. PubMed ID: 22716277
[TBL] [Abstract][Full Text] [Related]
2. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
3. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
5. Novel targets for VEGF-independent anti-angiogenic drugs.
Petrillo M; Scambia G; Ferrandina G
Expert Opin Investig Drugs; 2012 Apr; 21(4):451-72. PubMed ID: 22339615
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA
Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
Ishak RS; Aad SA; Kyei A; Farhat FS
Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
[TBL] [Abstract][Full Text] [Related]
9. Targeting VEGF in lung cancer.
Das M; Wakelee H
Expert Opin Ther Targets; 2012 Apr; 16(4):395-406. PubMed ID: 22439677
[TBL] [Abstract][Full Text] [Related]
10. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
11. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
13. Response to anti-angiogenesis: an ever changing feature.
Bertolini F
Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
[TBL] [Abstract][Full Text] [Related]
14. Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors.
Vuorio T; Jauhiainen S; Ylä-Herttuala S
Expert Opin Biol Ther; 2012 Jan; 12(1):79-92. PubMed ID: 22115316
[TBL] [Abstract][Full Text] [Related]
15. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Tonra JR; Hicklin DJ
Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
[TBL] [Abstract][Full Text] [Related]
16. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
17. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
Kakeya H; Osada H
Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
[TBL] [Abstract][Full Text] [Related]
18. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
20. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
